MacroGenics Doses First Patient in Phase 1 Trial of MGC030 for Advanced Solid Tumors

• MacroGenics dosed the first patient in a Phase 1 trial of MGC030 for advanced solid tumors, announced Oct. 15, 2026.
• The antibody-drug conjugate becomes its third ADC in active clinical development.
• Preclinical findings showed encouraging antitumor activity; the clinical trial will assess safety, tolerability and preliminary antitumor activity.
• Dose escalation will enroll up to 54 participants, with potential expansion at selected doses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610151605PRIMZONEFULLFEED9846812) on October 15, 2026, and is solely responsible for the information contained therein.